AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...

Children younger than 5 exhibited higher risk for hospital readmission after initial admission for respiratory syncytial virus than after initial admission for influenza or human metapneumovirus, ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...